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Retinoblastoma is a rare pediatric tumor of the retina, caused by the homozygous loss
of the Retinoblastoma 1 (RB1) tumor suppressor gene. Previous microarray studies have
identified changes in the expression profiles of coding genes; however, our understanding
of how non-coding genes change in this tumor is absent. This is an important area of
research, as in many adult malignancies, non-coding genes including LNC-RNAs are
used as biomarkers to predict outcome and/or relapse. To establish a complete and
in-depth RNA profile, of both coding and non-coding genes, in Retinoblastoma tumors,
we conducted RNA-seq from a cohort of tumors and normal retina controls. This analysis
identified widespread transcriptional changes in the levels of both coding and non-coding
genes. Unexpectedly, we also found rare RNA fusion products resulting from genomic
alterations, specific to Retinoblastoma tumor samples. We then determined whether
these gene expression changes, of both coding and non-coding genes, were also
found in a completely independent Retinoblastoma cohort. Using our dataset, we then
profiled the potential effects of deregulated LNC-RNAs on the expression of neighboring
genes, the entire genome, and on mRNAs that contain a putative area of homology.
This analysis showed that most deregulated LNC-RNAs do not act locally to change the
transcriptional environment, but potentially function to modulate genes at distant sites.
From this analysis, we selected a strongly down-regulated LNC-RNA in Retinoblastoma,
DRAIC, and found that restoring DRAIC RNA levels significantly slowed the growth of the
Y79 Retinoblastoma cell line. Collectively, our work has generated the first non-coding
RNA profile of Retinoblastoma tumors and has found that these tumors showwidespread
transcriptional deregulation.
Keywords: retinoblastoma, LNC-RNAs, RNA-sequencing, LNC targeting, DRAIC
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INTRODUCTION
The protein produced from the Retinoblastoma 1 (RB1) tumor
suppressor gene, pRB (1), functions as a molecular scaffold,
to bind to and repress the activator E2 promoter binding
factor (E2F) transcription factors 1-3 (E2F1-3) (2). The activator
E2F’s bind to the promoters of genes necessary for cell cycle
progression (3) and apoptosis and induce their expression (2).
In this context, pRB plays a central role in controlling the cell
cycle and acts a critical check-point to prevent cells with DNA
damage or other abnormal features from continuing to divide
(4). This activity has led to the widespread inactivation of the
pRB/E2F in cancer cells, and a number of genomic events disrupt
pRB function (1, 5) or lead to constitutive phosphorylation, and
inactivation pRB (6–10). Loss of pRB-activity occurs in the vast
majority of tumor types, however background mutations, and
the very high frequency of pRB and p53 co-inactivation has
made understanding the transcriptional changes solely driven by
pRB-loss in tumors difficult to determine.
To identify transcriptional changes to both messenger RNA
(mRNA) and long non-coding RNAs (LNC-RNAs) dependent
on pRB-loss, we used RNA-sequencing (RNA-seq) to profile
Retinoblastoma tumors and normal retinal tissue from patients.
Retinoblastoma is a rare pediatric tumor of the Retina that
affects around 6,000–8,000 children every year (11, 12). There
is currently no targeted therapy for Retinoblastoma (13–
16) and many patients suffer secondary tumors (17, 18), or
developmental defects, due to treatment. In over 95% of cases,
the development of this tumor is driven the homozygous
deletion of the Retinoblastoma 1 (RB1) tumor suppressor
gene, on chromosome 13p14 (1). The remaining ∼5% of
Retinoblastoma’s are caused by the amplification of the V-
Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma
Derived Homolog (N-MYC) gene (19, 20). Loss of TP53 or the
upregulation of negative regulators of p53, including MDMX, is
also common in Retinoblastoma (21).
As these tumors are collected from pediatric patients,
they contain very few genomic alterations and represent an
ideal resource for understanding the coding and non-coding
transcriptional effects driven by pRB-loss. Determining how loss
of pRB changes cells is important for expanding our treatment
options for patients with Retinoblastomas, and may provide
insights into how RB1 contributes to additional tumor types
(22). To expand on previous microarray studies (14, 23–25),
we conducted the first in-depth RNA-sequencing (RNA-seq)
analysis of Retinoblastoma. This analysis builds upon the mRNA
profiling of earlier studies and expands the coverage of non-
coding changes.
RESULTS
RNA-Sequencing From Retinoblastoma
and Retinal Tissue
To determine how the loss of the Retinoblastoma 1 (RB1)
tumor-suppressor gene changes the expression of coding and
non-coding RNAs in tumors, we conducted RNA-sequencing
(RNA-seq) from 7 Retinoblastoma patients. The tumors were
removed from patients between 8 months and 6 years of age,
with a mean age of 2 years and 8 months. Importantly, the
gender demographics of these patients is equally split between
males (4) and females (3), and between invasive (3), and non-
invasive (4) tumors. A complete list of the patient and control
sample demographics is included in Table 1. We also conducted
RNA-seq on control Retinal samples and incorporated additional
public retinal datasets to build a transcriptional profile of normal
retina (Supplementary Tables 1, 2). The RNA-seq profiles of
these samples were then separated, and clustered to measure
transcriptional changes in Retinoblastoma tumors (Figure 1A).
Using normalized values, we found significant and recurrent
changes in both coding and long non-coding RNAs (LNC-RNAs)
within the tumors (Figure 1B).
We then used Gene Ontology (GO) analysis (26, 27)
to identify biological processes altered in Retinoblastoma
tumors. In accordance with previous microarray studies,
we found DNA replication and mitotic progression
genes were strongly upregulated and retina specific genes
downregulated in tumors (Supplementary Figures 1A–C).
In addition, the majority of upregulated genes (>3-
fold) were either E2F (28, 29) or MYC target genes
(Supplementary Figures 1D,E) (30). To independently
test the levels of coding gene expression, we used RT-
PCR to measure the levels of a subset of E2F-target genes
from an independent cohort of tumors and retina controls
(Supplementary Figure 2). This analysis confirmed that
E2F target genes are consistently increased in RB1-mutant
Retinoblastomas (Figure 1C). We next compared our
Retinoblastoma transcriptional profile to datasets from other
pediactric tumors. From this analysis, we found very limited
overlap suggesting the gene signature of Retinoblastoma is
unique (Supplementary Figure 3A).
Aberrant RNA Processing Events
in Retinoblastoma
Previous microarray studies of Retinoblastoma tumors have
provided important insights into the coding RNA changes
in these tumors. However, these technologies are limited in
their capacity to detect RNA fusion products. To address
this, we searched for RNA-fusions within our RNA-seq
dataset and identified 22 putative RNA fusion events. From
this collection, we selected two putative RNA hybrids for
detailed examination, using RT-PCR. For this RT-PCR based
evaluation, we used 10 normal retinal tissue samples and a
larger cohort (>13) of Retinoblastoma tumors (Figure 1D).
From this work, we were able to detect RNA from the
LSG1-TMEM44 RNA fusion in 73% of tumors, whilst
only 1 control sample had detectable levels (Figures 1D,E,
Supplementary Figure 3B). In contrast, the CIRBP-C19orf24
fusion occurred in 31% of tumors but was not found in
control samples (Figures 1D,F, Supplementary Figure 3B).
We then sequenced these RT-PCR products and confirmed
the RNA fusion (Figures 1E,F). From this analysis, we
have identified and confirmed the presence of RNA-fusions
in Retinoblastoma.
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TABLE 1 | Clinical characteristics of the patients and tissue used in the RNA-Seq analysis.
Patient
ID
RNASeq_Ref
ID
Pathology
Ref ID
Age at the
time of
enucleation
Histo pathology report Sex Unilateral/
Bilateral
Chemo
status
before
enucleation
Invasiveness
C1 48428 12 years
Retina
12 Y N/A Unknown N/A N/A N/A
1 48429 67/13 6 Y Retinoblastoma, poorly differentiated, focal
invasion of choroid measuring more than 3mm.
There is prelaminar and laminar invasion of the
optic nerve present. Hyperchromatic cells are
seen in the trabecular meshwork and over the
iris surface. The post laminar portion and the
surgical end of optic nerve are free from tumor
cells.
Male OD (IIRC
Grade E)
No Invasive
2 48430 1563/15 3 Y Retinoblastoma, poorly differentiated,
endophytic growth pattern. No invasion of
choroid. No invasion of optic nerve.
Male OS (IIRC
Grade E)
No Non-Invasive
C2 48431 5 years Retina 5 Y N/A Unknown N/A N/A N/A
3 48432 1561-15 2 Y Retinoblastoma well differentiated. No invasion
of iris.No invasion of choroid and optic nerve.
Female OD (IIRC
Grade E)
No Non-Invasive
4 48433 1630-15 3 Y Retinoblastoma, poorly differentiated. No
invasion of choroid. No invasion of optic nerve.
Female OD (IIRC
Grade D)
No Non-Invasive
5 48434 647-13 1 Y Retinoblastoma, well differentiated, focal retinal
pigment epithelial invasion, there is no invasion
of choroid. Preliminar invasion of optic nerve is
seen. The laminar, post laminar and surgical
end of optic nerve is free from tumor.
Female OD Yes (Two
cycles)
Invasive
6 48435 1548-14 3 Y Retinoblastoma poorly differentiated. Male OS (IIRC
Grade D)
No Non-Invasive
There is no invasion of choroid. There is No
invasion of optic nerve. No invasion into iris
stroma.
C3 48436 22 years
Retina
22 Y N/A Unknown N/A N/A N/A
7 48437 768-13 8 Months Retinoblastoma, well differentiated, no invasion
of choroid. There is prelaminar, laminar, post
laminar invasion of optic nerve. Separate
section at the surgical end of optic nerve is free
from tumor cells. There is no scleral invasion.
Male OD (IIRC
Grade E)
No Invasive
Non-coding RNA Changes in Tumors
Very little is known about how loss of the pRB tumor-suppressor
gene affects the transcription of LNC-RNAs in tumors. To
address this, we next analyzed the expression patterns of LNC-
RNAs in Retinoblastoma and found widespread alterations in
LNC-RNA levels (Figure 2A). Subsets of LNC-RNAs were both
up and downregulated in tumors and could be used to sub-
classify tumors from normal tissue (Figure 2A). This analysis
identified groups of LNC-RNAs that show significant alterations
in their levels (Figure 2B). As many of these genes are poorly
characterized, we chose to measure the levels of a subset of these
de-regulated LNC-RNAs in an independent tumor and control
cohort. We measured each candidate LNC-RNA using RT-PCR
and found that our results correlated well with our RNA-seq
analysis. Up-regulated LNC-RNAs (LNC00152 and LNC01053)
were consistently significantly increased (Figures 2C,D), whilst
down-regulated LNC-RNAs (LNC01137 and LNC00575) were
decreased in 2 of the 3 tumors (Figures 2E,F). Predicting
how LNC-RNAs may function in tumors is challenging and is
dependent on a number of factors. We next investigated how
the expression of each deregulated LNC-RNA correlated with
the expression of genes in the entire genome, locally, or in
trans. We first compared the genomic loci of significantly up or
downregulated LNC-RNAs, with the expression of deregulated
coding genes that displayed reciprocal patterns. From this
assay, we found that de-regulated LNC-RNAs (either up or
downregulated) showed statistically significant anti-correlates
with coding genes, however, these patterns were not restricted
by chromosomal location (Figure 2G). This analysis suggested
that the majority of transcriptionally altered LNC-RNAs may not
affect the local expression of genes.
Despite this global pattern, we did identify a subset of
LNC-RNAs, whose changes in expression correlated with that
of their neighboring gene. In particular, reduced expression
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FIGURE 1 | Coding RNA changes and RNA fusion products in Retinoblastoma tumors. (A) Heat map of transcriptional changes in Retinoblastoma tumors and
normal retinal samples. (B) Volcano plot of the log fold change (logFC) (x-axis) and the log p-value (logPval) (y-axis) of the coding (mRNA) RNA changes in tumors and
normal tissue. (C) RT-PCR Relative expression of Six E2F targets genes (ORC1, SMC2, SMC4, MCM4, E2F1, and CENPE) from four control retinal tissues and three
Retinoblastoma tumors from an independent cohort (*p < 0.05). (D) Table detailing the RNA fusion products detected in the RNA-seq data, including independent
testing in Retinoblastoma primary tumors and control retinal samples. (E) Screenshot and sequencing data of the LSG1 and TMEM44 fusion RNA detected in
Retinoblastoma tumors. (F) Screenshot and sequencing data of the CIRBP and C19orf24 fusion RNA detected in Retinoblastoma tumors.
of the LNC-RNAs: CERNA1, AC025259.3, AL139220.2, and
AC090360.1, all correlated with lower mRNA levels of the
genes that they overlap with, including: GNB5, NR4A1,
SLC6A9, and RBFADN (Figure 3A). Interestingly, when we
measured adjoining LNC-RNA: mRNA pairs, we observed
two different patterns. In the cases of NUP50-AS1 and
LNC01431, we found that LNC-RNA downregulation was
associated with increased expression of their neighboring genes,
NUP50 and NXT1 (Figure 3B, Black and Blue bars). More
commonly however, we found that reduced LNC-RNA levels,
AC103706.1, EPB41L4A-AS2, AC110716.2, AL391121.1, and
LNC02091, was correlated with lower mRNA levels of their
adjoining genes, namely: ST3GAL1, EPB41L4A, NMNAT3,
TRIM8, and DOC2B (Figure 3B). Analysis of the correlation in
expression of proximal LNC-RNAs and their neighboring genes
identified both anti (AC027287.2-NEUROD4) and positively
correlated associations (AL354872.2-CTH, AL023284.4-MAP7,
LNC00575-SCD5, and LNC01844-ARHGAP26) (Figure 3C).
Collectively, this analysis identified a subset of LNC-RNAs and
their neighboring genes that have altered expression patterns
in Retinoblastoma.
The majority of LNC-RNA expression changes in these
tumors do not correlate with genes geographically associated
with them. We next examined whether LNC-RNAs with altered
mRNA levels correlate with the expression any other genes
across the genome. To do this, we stratified the LNC-RNAs
and measured the average correlation of changed mRNAs. From
this analysis, we identified several LNC-RNAs that show both
average positive and negative relationships with the altered
mRNAs (Figure 3D). We next selected 10 of these LNC-
RNAs for closer examination and found that each LNC-RNA
was significantly correlated to many deregulated genes in
Retinoblastoma (Figure 3E). Collectively, this analysis shows that
LNC-RNAs have diverse and putatively complex relationships
with the expression of their neighboring genes and genes
throughout the genome.
Non-coding RNA Changes and Their
Putative Effects in trans
We next investigated the putative interaction between
deregulated LNC-RNAs in Retinoblastoma and mRNAs
that contain regions that could be putatively bound by the
LNC-RNA. To evaluate this, we identified gene expression
changes in coding genes that had highly homologous regions
to those of de-regulated LNC-RNAs. We then computationally
measured the potential for RNA-RNA duplexes to form, between
the coding gene, and the LNC-RNA (31). Our analysis used the
RNA-RNA interaction database (31).
This analysis of the putative targets of upregulated LNC-RNAs
in Retinoblastoma tumors identified a group of 68 genes that
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FIGURE 2 | Non-coding RNA expression changes in Retinoblastoma tumors. (A) Heat map of non-coding transcriptional changes in Retinoblastoma tumors and
normal retina samples. (B) Volcano plot of the log fold change (logFC) (x-axis) and the log p-value (logPval) (y-axis) of the non-coding RNA changes in tumors and
normal tissue. (C) RT-PCR Relative expression of LNC00152 from four control retinal tissues and three Retinoblastoma tumors from an independent cohort (*p <
0.05). (D) RT-PCR Relative expression of LNC01053 from four control retinal tissues and three Retinoblastoma tumors from an independent cohort (*p < 0.05). (E)
RT-PCR Relative expression of LNC01137 from four control retinal tissues and three Retinoblastoma tumors from an independent cohort (*p < 0.05). (F) RT-PCR
Relative expression of LNC00575 from four control retinal tissues and three Retinoblastoma tumors from an independent cohort (*p < 0.05). (G) Heat map of
non-coding transcriptional changes from Retinoblastoma tumors, compared to anti-correlated deregulated mRNA clustered by genomic location.
are increased and 6 genes that are decreased (2-fold changed
and p > 0.05) (Figure 4A, UP: Dark green balls, DOWN:
Bright red balls). Gene Ontology of these increased mRNAs
(>2-fold), that are putatively targeted by upregulated LNC-
RNAs, showed that they function in processes supporting cell
division and microtubule function (Figure 4B). In the genes
downregulated (2-fold lower), we identified enrichments in
genes modulating cellular adhesion and retinal development
(Figure 4C). We next determined the putative targets for the
LNC-RNAs downregulated in Retinoblastoma tumors, using the
same stringency parameters. From this, we found 54 putative
mRNAs that are increased and 8 genes with decreased expression
(2-fold changed and p > 0.05) (Figure 4D, UP: Dark green
balls, DOWN: Bright red balls). Gene Ontology analysis of these
increasedmRNAs, that are putatively targeted by down-regulated
LNC-RNAs, showed that cell attachments and proliferation
factors are the molecular processes putatively changed by lower
LNC-RNA levels (Figure 4E). Putative LNC-RNA targets with
lower expression levels in Retinoblastoma tumors are involved
in muscle associated processes (Sarcolemma) and Endocytosis
(Figure 4F). Collectively, this analysis highlights the potential
complexity of LNC-RNA function in Retinoblastoma.
We next investigated how modulating the levels of a down-
regulated LNC-RNA in Retinoblastoma affected the growth of
Y79 Retinoblastoma cells. For this, we selected the DRAIC
LNC-RNA, as DRAIC levels are strongly decreased in tumors
(Figure 5A) and in our independent Retinoblastoma cohort
(Figure 5B). We next tested how DRAIC over-expression
contributed to the growth of Retinoblastoma cells. To do this, we
transfected cells with either empty pCDNA plasmids or pcDNA-
DRAIC over-expression plasmids (Figure 5C) (32) andmeasured
Y79 growth. From these experiments, we found that DRAIC
over-expression significantly slows Y79 growth (Figure 5D),
without promoting cell death.
DISCUSSION
Inactivation of the RB/E2F pathway is a common feature
of cancer (22). In this analysis, we sought to understand
how the homozygous deletion of the RB1 gene changed the
transcriptional profile of both coding and non-coding genes
in the rare pediatric tumor, Retinoblastoma. To do this, we
compared the gene expression of Retinoblastoma tumors with
that from normal retinal tissue using RNA-sequencing. This
represents the first time that such an approach has been
used to generate a complete transcriptional profile of these
tumors and builds upon previous coding RNA studies (23–
25, 33). Our work expands our coverage of the genome for
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FIGURE 3 | Predicting local and distant potential LNC-RNA: RNA regulation. (A) Graph of significantly changed LNC-RNA: mRNA pairs from overlapping loci. (B)
Graph of significantly changed LNC-RNA: mRNA pairs from adjoining loci. (C) Graph of significantly changed LNC-RNA: mRNA pairs from proximal loci. (D) Average
correlations of deregulated LNC-RNAs to mRNA changes in Retinoblastoma tumors (Black dots: Average positive correlation, Red dots: Average negative correlation).
(E) Examples of deregulated LNC-RNAs (FAM138A, DRAIC, FAM138D, FAM138E, HAR1A, FAM138B, LNC00092, DUBR, LNC00606, and LNC01586) and relative
correlation coefficient to coding gene changes.
Retinoblastoma and includes the expression from non-coding
regions of the genome, including long non-coding RNAs (LNC-
RNAs), anti-sense RNAs, and transposable elements. This new
in-depth analysis of RNA changes, coupled with our recent
proteomic profiling of this cohort of Retinoblastoma (34),
provides a new resource for the Retinoblastoma and RB-loss
research community.
In agreement with previous microarray based studies (23–
25, 33), we find very strong transcriptional upregulation of E2F
target genes involved in cell cycle progression and apoptosis. In
contrast, p53 and MYC target genes are only mildly affected.
Most of the down regulated genes are associated with retina
cell differentiation and ocular development. These results are
consistent with retinal cells when they abnormally differentiate
and cause lineage specific gene expression changes.
As RNA-seq provides a unique platform for detecting
rare fusion or trans-spliced transcripts, we investigated the
frequency of these events in Retinoblastoma. There are multiple
potential mechanisms for generating the hybrid RNAs, including
chromosomal translocation, deletions or inversions, gene fusion,
or aberrant splicing events. We independently evaluated each
dataset to identify potential fusion transcripts, as these have
been shown to have potential oncogenic (35) or predictive
roles (36) in different malignancies. Our analysis revealed a
small subset of putative fusion transcripts in our tumor cohort
between consecutive genes, where transcripts of the two genes
are transcribed into one chimeric transcript by splicing out the
intergenic region. Further independent testing of these candidate
genes, using RT-PCR, found 2 bone fide fusion transcripts that
occurred at high frequencies in Retinoblastoma tumors, relative
to normal retinal tissue. Although much more work is needed to
test the possible function of these RNAs, this work suggests that
RNA-fusion products are common in Retinoblastoma tumors.
This work represents the first genome-wide profiles of non-
coding RNA changes in Retinoblastoma tumors. Our profiles
identified significant and widespread differences in the levels
of anti-sense, LNC-RNAs and transposable elements in tumor
samples, compared to normal retinal tissue. Although there
is some inter-tumoral variation between LNC-RNA levels, the
majority show consistent changes which could be independently
confirmed in an unrelated Retinoblastoma cohort. Determining
the potential roles of LNC-RNAs can be challenging, as they
can potentially function via many mechanisms to affect local or
distant gene expression or directly interact with other RNAs to
alter their stability and/or translation capacity. To address this
complex question, we conducted an exhaustive analysis of how
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FIGURE 4 | Putative Molecular processes regulated in-trans by significantly changed LNC-RNAs in Retinoblastoma. (A) Volcano plot of expression of mRNAs
targeted by upregulated LNC-RNAs in Retinoblastoma tumors. Green line represents 2-fold increase, Red line represents 2-fold decrease, Blue lines represent
statistically significant cutoff of p-value of 0.05. Deep Green circles: p < 0.05 and >2-fold increased, Light Green circles: p > 0.05 and >2-fold increased, Black
Circles: unchanged, Light Red circles: p > 0.05 and >2-fold decreased and Deep Red circles: p < 0.05 and >2-fold decreased. (B) Gene Ontology of the mRNAs
upregulated and putatively targeted by upregulated LNC-RNAs. (C) Gene Ontology of the mRNAs downregulated and putatively targeted by upregulated LNC-RNAs.
(D) Volcano plot of expression of mRNAs targeted by downregulated LNC-RNAs in Retinoblastoma tumors. Green line represents 2-fold increase, Red line represents
2-fold decrease, Blue lines represent statistically significant cutoff of p-value of 0.05. Deep Green circles: p < 0.05 and >2-fold increased, Light Green circles: p >
0.05 and >2-fold increased, Black Circles: unchanged, Light Red circles: p > 0.05 and >2-fold decreased and Deep Red circles: p < 0.05 and >2-fold decreased.
(E) Gene Ontology of the mRNAs upregulated and putatively targeted by downregulated LNC-RNAs. (F) Gene Ontology of the mRNAs downregulated and putatively
targeted by downregulated LNC-RNAs.
FIGURE 5 | Re-Expression of the DRAIC LNC-RNA slows the growth of Retinoblastoma cell lines. (A) Expression levels of DRAIC LNC-RNA in normal Retina vs.
Retinoblastoma tumors (p < 0.05). (B) RT-PCR of DRAIC levels in an independent tumor cohort (p < 0.05). (C) RT-PCR of Y79 cells expressing either pcDNA-DRAIC
or an empty pcDNA control. (D) Growth assay of Y79 cells transfected with either pcDNA-DRAIC or an empty pcDNA control.
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altered LNC-RNAs may contribute to the relative mRNA levels
in Retinoblastoma.
First, we investigated how each altered LNC-RNA correlated
with deregulated mRNA levels, based on chromosome location.
These predictions suggest that although each LNC-RNA did
show anti-correlates with several mRNAs, these were spread
throughout the genome, suggesting that most of the changed
LNC-RNAs in Retinoblastoma do not function in cis. In
agreement with this hypothesis, we detected only 16 LNC-RNAs
that showed tight expression correlations with their overlapping,
adjoining or proximal gene partners. Second, by generating
correlation efficiencies for each of the 400most deregulated LNC-
RNAs in our tumors to the mRNA changes, we found that many
LNC-RNAs showed a relative positive or negative relationship to
mRNA levels. Third, using new LNC-RNA: mRNA interaction
platforms followed by gene ontology analysis of these putative
interactions, we found that many up and down regulated LNC-
RNAs have strong potential interactions with genes involved in
cellular processes that sustain Retinoblastoma growth including
cell division and cell attachment. These data provide a complete
analysis of the transcriptional changes for both coding and non-
coding genes in the pediatric Retinoblastoma tumor.
To measure how altered LNC-RNAs may contribute to
Retinoblastoma growth, we evaluated how re-expressing a down-
regulated LNC-RNA in Y79 Retinoblastoma cell lines altered cell
number. DRAIC expression slowed Y79 cell growth compared
to controls, in support of previous data from lung cancer,
showing that reducing the expression of DRAIC back to
physiological levels changes the proliferation potential of cells.
These experiments show that modulating the levels the DRAIC
LNC-RNA does affect Retinoblastoma cells.
METHODS
Patient Samples for RNA-seq
The 2 normal Retinas were obtained from donor eye balls
from the PU Shah eye bank. The age was 12 and 22 years,
respectively. The Retinoblastoma tumors were obtained
from informed consent provided by the parents of the
children undergoing treatment at Sankara Nethralaya, India.
The protocol was approved by institutional review board
on Ethical practices for research at Sankara Nethralaya.
The pathological characterizations of the tumors are
presented in Table 2. For RNA-sequencing studies, the
tumors and retinas were stored at−80
◦
C until further use.
The medical record pathology numbers of these samples
were de-identified before the tumors were released by the
hospital. Each sample was then assigned an identification
number by the hospital. The RNA was then used for
RNA-sequencing. The samples were named from 48,428
to 48,437.
RNA Extraction for RNA-seq
The Retinae and tumors were thawed, and RNA was extracted
using TRIzol reagent (#15596026, Thermo Fisher Scientific)
according to the manufacturer’s instructions. The samples
were homogenized in TRIzol reagent and incubated at room
temperature for 5min. Next, chloroform was added, and the
tubes were mixed vigorously for 15 s followed by incubation
at room temperature for 2–3min. Next, the samples were
centrifuged at 4◦C for 15min at 12,000 g. RNA, which is
part of the aqueous phase, is collected cautiously and is
precipitated using isopropanol, followed by 75% ethanol
washes. After the washes, RNA pellet is dried completely
(5–10min) before re-suspending in nuclease free water.
Total RNA thus extracted is qualified on 2,200 Tape Station
using the RNA specific Tapes and reagents (#5067-5576,
5577, Agilent Technologies). Quantification of the RNA
was done using Qubit 3.0 Fluorimeter (#Q33216, Thermo
Fisher Scientific) with an RNA HS Assay (#Q32852, Thermo
Fisher Scientific).
RNA Library Preparation and RNA-seq
Once the RNA passed QC, it was taken up for library
preparation using the TruSeq RNA Library Prep Kit V2
(#RS-122-2001/RS-122-2002, Illumina Inc.). During the library
preparation, the Ribosomal RNA (rRNA) were removed
using biotinylated, rRNA specific oligo’s combined with Ribo-
zero rRNA removal beads (#MRZG12324, Illumina Inc.).
Following purification, the Ribo-depleted RNA is subjected
to fragmentation in the presence of divalent cations at
elevated temperatures. The cleaved RNA fragments were
copied into first strand cDNA using reverse transcriptase and
random primers. Then, second strand cDNA synthesis was
performed, using DNA polymerase I and RNase H. These
cDNA fragments will go through the process of repairing
the ends, addition of a single “A” base, followed by ligation
of the adapters. The ligation product was purified using
Agencourt AMPure XP beads (#A63882, Beckman Coulter)
and enriched using PCR to create the final cDNA library
for sequencing. After a final cleanup with Agencourt AMPure
XP beads, the library was quantified using Qubit DNA Assay
and the fragments were assessed using DNA Tape Station
D1000 Screen Tape (#5067-5582,5583, Agilent Technologies).
The quantified libraries were then clonally amplified on a
cBOT and sequenced on the HiSeq2500 with 100 bp paired
end chemistry. 5′AATGATACGGCGACCACCGAGATCTAC
ACTCTTTCCCTACACGACGCTCTTCCGATCT3′
The TruSeq Universal Adapter. The TruSeq Illumina Index
Adapter consisted of following sequence: 5′GATCGGAAGAGC
ACACGTCTGAACTCCAGTCAC[INDEX]ATCTCGTATGCC
GTCTTCTGCTTG3′.
Bioinformatics
The raw fastq files generated in sequencing were first subjected
to a quality check to filter out substandard data. During quality
control, the following parameters were checked: base quality
score distribution, sequence quality score distribution, average
base content per read, GC distribution in the reads, PCR
amplification issue, check for over-represented sequences and
finally, adapter trimming. Based on the QC report, the reads
having a phred quality score of Q30 were either removed or
trimmed as per requirement. The adapter trimming was done
using fastq-mcf v-1.04.676 and cutadapt v-1.8dev (ftp://ftp.
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TABLE 2 | Primers.
Target Forward primer Reverse primer
1 ORC1 CCCTATCAGTGGGGGACAGA ATGGGGAGTAGAGGTCGCTT
2 SMC2 TCAGCCAGATGTATTGCACCA CACATGAACGTTGTCAGGGC
3 SMC4 CCTGTTGTCATGCACTGGACT TCGGTCATCTTTTTCGCCCA
4 TOP2A AGCTGGATCAGTGGCTGAAAT GCCTGGTACCAAACTGACCA
5 MCM4 TGTTTGCTCACAATGATCTCG CGAATAGGCACAGCTCGATA
6 E2F1 ACTCCTCGCAGATCGTCATCATCT GGACGTTGGTGATGTCATAGATGCG
7 CENPE GATTTGGATGAATTTGAGGCTCT ACTTCTGCATGCTTAACTAAATTCT
8 LNC00505 GTGAAGACCCCCTTTCCCAC AGATGCTGGCTAGTTTGGGG
9 LNC01053 CTGTCCCTATCTGGAGCCCT GAAAGATGTGTGCGTGACCG
10 LNC00152 CCAGCACCTCTACCTGTTGC GCCAGACAAATGGGAAACCG
11 LNC01155 ACCTTCTTGGCCCTGCTTAG TAGAGGGTGGCCCTTAGTGA
12 LNC-PINT CGCAGAGGGACAAATCCAGT CCCCGGAGAGCAATGAGTTT
13 LNC00844 TCTGATAGGAGGATGGGGGTG CTTAGCCATGCAAGAAACCTCC
14 LNC01137 AGCGATCTTGGGGGAAGTTG GGGTTAGGGAGTGGCATCAC
15 LNC00575 GAATTGGCACAGATCCAGAGC GGTTCTCATCCCCTGAAGTCT
16 LNC00606 CACTGCTTTGGTCAGGGAGT ACTCTCCTTGTCAGCGGTTG
17 β-actin TCACCCACACTGTGCCCATCTACG CAGCGGAACCGCTCATTGCCAATG
18 LSG1_TMEM44 AAGCTGCTGTACTGCCATCCTC CAGGAGGAGGCGCAGATC
19 CIRBP_C19orf24 AGGACTCGGGGAAGGGTG ATTCCGGGACTCAAACACCG
20 DRAIC TGAACTCAACTCCTGAGAAGGAC CGCTCTCAGACTCTTCAGTTCTC
21 β-actin TCACCCACACTGTGCCCATCTACG CAGCGGAACCGCTCATTGCCAATG
ensembl.org/pub/release75/gtf/homo_sapiens/Homo_sapiens.
GRCh37). The processed data were then checked for the presence
of unwanted sequences or contamination (e.g., non-polyA tailed
RNAs, mitochondrial genome sequences, ribosomal RNAs,
transfer RNAs, adapter sequences, and others), and those
contaminations were removed using Bowtie2 v-2.2.4 (37). The
first step of analyzing the processed RNA-seq data is to align
them to the reference human genome. To do this, the paired-end
reads were aligned to reference human genome, GRCh37/hg19
(2), using HISAT v-0.1.7 (38). The aligned reads were then
subjected to expression estimation of individual genes and
transcripts by calculating the FPKM values (Fragments Per Kilo
base of transcript per Million mapped reads) using cufflinks
v-2.2.1 (39). Finally, the differential expressions of genes were
carried out using cuffdiff v-2.2.1 & DESEQ2 (40). Genes with a
log2 fold change of more than 1 or less than −1 and a p < 0.05
were termed as differentially expressed genes.
Global changes in mRNA and biological triplicate samples
per experimental condition were analyzed using RNA-Seq,
specifically with the consensus Bioconductor (41, 42) workflow;
FASTQC for trimming, genomic alignment in Rsubread, and
differential expression with limma (43) and visualization
(pheatmap) and volcano plots were generated in ggplot2.
Subsequently, the Pearson’s correlation was measured for
each of the top differentially expressed mRNAs or lncRNAs,
and a cross-correlation of q values was generated. These
significant correlations, >0.3 or <-0.3, were also visualized in
pheatmap with the chromosome and genomic start location
used to annotate each species. Finally, the 10 lncRNA with
the greatest sum of correlations were selected and the
mRNA correlations illustrated with the most significant mRNA
species identified.
LNC-RNA Target Prediction
LNC-RNAs that were statistically significantly up or
downregulated in Retinoblastoma tumors, compared to
normal retinal tissue, were profiled to determine their putative
mRNA targets. LNC-RNAs were retained for this analysis if
they had SUMENERGY scores of above 2,000 for at least 10
targets and all putative substrates with SUMENERGY above
1,500 were included. This step was taken to reduce the number
of weak substrates included in the Gene Ontology. LNC-RNAs
that did not have this criteria were excluded, as were mRNAs
that were predicted in >4 LNC-RNAs as this was taken as a
false positive. LNC-RNAs were entered into the RNA-RNA
interaction database (human) and the predicted targets were
extracted. These mRNAs, their associated SUMENERGY
score and change in expression, were used to sub-group the
putative LNC-RNA targets in the tumor cohort. These groups
were then used in Gene Ontology analysis using DAVID
(44, 45).
LNC-RNA Neighboring Gene Analysis
LNC-RNAs are known to regulate gene expression in cis-acting
and trans-acting ways. We carried out neighboring gene
analysis and LNC RNA-mRNA interaction analysis to identify
the probable targets of LNC-RNA. LNC-RNAs identified to
be differentially expressed were classified based on genomic
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location, and this was done with any other gene (irrespective of
coding nature). The following distance parameters were used:
Overlap is within any other gene, Adjoining is within 5 kb of
another gene, Proximal is within 10 kb of another gene, Others
>10 kb of another gene. Those neighboring protein-coding genes
that were found to be significantly expressed were considered to
be influenced by LNC-RNA.
Tumors and RNA Extraction Method
for RT-PCR
Retinoblastoma samples were provided by the Cooperative
Human Tissue Network, a National Cancer Institute supported
resource. Other investigators may have received samples from
these same tissue specimens. Normal retinal tissue was obtained
from warm autopsy samples from Mohamed Abdel-Rahman at
the Ohio State University. RNA was extracted from each of
the three retinoblastoma tissue samples and four retina tissue
samples that were received snap frozen. To each sample, 1mL
TRIzol Reagent (Invitrogen) was added to 10mg of tissue and the
samples were homogenized using a homogenizer and incubated
at room temperature for 5min. 0.2mL of chloroform was added
to the samples and incubated at room temperature for 2min, then
the samples were centrifuged for 15min at 12,000 × g at 4◦C.
The upper aqueous phase containing the RNA was transferred
to a new tube and 0.5mL of isopropanol was added, then this
mixture was incubated at room temperature for 10min. The
samples were centrifuged for 10min at 12,000 × g at 4◦C and
a white pellet formed. The supernatant was discarded and the
pellet re-suspended in 1mL of 75% ethanol. The sample was
briefly vortexed and then centrifuged for 5min at 7,500 × g
at 4◦C. The supernatant was discarded and the RNA pellet
air dried for 10min. The pellet was re-suspended in 20 µL
of RNase-free water and incubated in a 60◦C water bath for
15min. The RNA was then quantified using a BioTek Epoch
Microplate Spectrophotometer.
Fusion Transcript Detection
EricScript framework (Version: 0.5.5b) is used for the discovery
of fusion transcripts in paired end RNA-seq data (cite PMID:
23093608). Following steps are performed by the EricScript: (1)
Mapping of the reads against the transcriptome (downloaded
from the EricScript website, Homo sapiens, Ensembl version 73,
Genome Build hg19/GRCh37), (2) Identification of discordant
alignments and building of the exon junction reference, (3)
Recalibration of the exon junction reference, (4) Scoring and
filtering of the candidate gene fusions. The data is visualized
using a custom webserver based on The JBrowse Genome
Browser (PMID: 19570905). A simple perl script was written
to filter through the list of candidate fusion transcripts and
explored using the JBrowse Genome Browser (http://hegemon.
ucsd.edu/RB-p1/fusion/fusion.php).The list was then manually
filtered using BLAST on the NCBI website.
cDNA Synthesis
cDNAwas prepared from 400 ng of RNA using theHigh Capacity
cDNAReverse Transcription kit (Applied Biosystems), according
to manufacturer’s protocol.
Quantitative RT-PCR
The expression of the specified target genes was quantified
by q-RT-PCR, using Fast Start Universal SYBR Green Master
with ROX (Roche), and was normalized to the expression
of β-actin and normal samples. Custom designed primers
were used.
Y79 Transfection
2 x 105 Y79 cells were seeded in a 24-well plate.
Six wells each were transfected with pcDNA-DRAIC
and pcDNA3-EmptyVector were transfected using
Lipofectamine2000, according to manufacturer’s
protocol. The plasmids were a kind gift of Anindya
Dutta (32).
Cell Culture
The Y79 cell line was grown in RPMImedium supplemented with
20% FBS and 1X penicillin-streptomycin and cultured at 37◦C,
5% CO2 incubator as per ATCC guidelines.
Cell Growth Assay
Fifteen microlitre aliquot of cells are taken and diluted 1:1 with
Trypan Blue solution. Cells are counted using a haemocytometer
and the total number of cells are calculated.
Data Access
Complete RNA-seq data from tumors and control retinal tissue
uploaded to the NCBI GEO datasets (GSE125903).
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